MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
MBX Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
MBX Biosciences, Inc. Common StockNASDAQ: MBX
Short-term Investments · Q3 FY2026 · quarter ended Sep 2026
Short-term investments rises 89.8% from a year ago
Short-term investments stood at $319.9M at the end of Q3 FY2026, up 89.8% from a year earlier and down 12.2% from the prior quarter. Over 3 fiscal years it compounded at +153.8% a year.
Context
- Short-term investments amounted to 63.9% of total assets at the end of Q3 FY2026, up 21.8 pp from a year earlier.
- Short-term investments increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether short-term investments keeps rising in the next quarterly balance sheet after a +89.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 298.42M USD
- Year-over-year change
- +40.2%
- 3-year CAGR
- +153.8%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 298.42M | +40.2% |
| FY2024 | 2024-12-31 | 212.8M | +324.3% |
| FY2023 | 2023-12-31 | 50.15M | +174.8% |
| FY2022 | 2022-12-31 | 18.25M | — |
Short-term Investments vs competitors
How MBX compares with its peers on the latest reported figures
- Peers report in different currencies, so short-term investments is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +89.8% is the 2nd highest of 5, against a peer median of -14.5%.
- Short-term investments amounts to 63.9% of total assets for MBX, versus a peer median of 41.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
KLRAKailera Therapeutics, Inc. | Jun 2026 | $786.44M USD | — | — | 64.9% |
| Jun 2026 | $375.91M USD | -51.4% | +65.6% | 72.0% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $319.9M USD | +89.8% | +153.8% | 63.9% |
| Sep 2026 | $280.96M USD | -22.8% | +17.6% | 63.4% | |
| Mar 2026 | $233.94M USD | +132.3% | +46.0% | 69.7% | |
| Mar 2026 | $52.64M USD | -6.2% | -11.5% | 19.6% | |
| Sep 2026 | €0 EUR | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding MBX) | — | -14.5% | +31.8% | 41.5% | |
Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.